Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE

INTRODUCTION: The current mainstay of the treatment of thrombotic antiphospholipid syndrome (APS) is long-term anticoagulation with vitamin K antagonists (VKAs) such as warfarin. Non-VKA oral anticoagulants (NOACs), which include rivaroxaban, have been shown to be effective and safe compared with wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, H, Doré, C J, Clawson, S, Hunt, B J, Isenberg, D, Khamashta, M, Muirhead, N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2015
Materias:
Special Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527976/
https://www.ncbi.nlm.nih.gov/pubmed/25940537
http://dx.doi.org/10.1177/0961203315581207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527976/
https://www.ncbi.nlm.nih.gov/pubmed/25940537
http://dx.doi.org/10.1177/0961203315581207

Ejemplares similares